Stocks and Investing Stocks and Investing
Mon, October 9, 2017
Fri, October 6, 2017
Thu, October 5, 2017

David Risinger Maintained (TEVA) at Sell with Decreased Target to $15 on, Oct 5th, 2017


Published on 2024-10-25 23:14:45 - WOPRAI, David Risinger
  Print publication without navigation


David Risinger of Morgan Stanley, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Sell with Decreased Target from $16 to $15 on, Oct 5th, 2017.

David has made no other calls on TEVA in the last 4 months.



There are 10 other peers that have a rating on TEVA. Out of the 10 peers that are also analyzing TEVA, 7 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Douglas Tsao of "Barclays" Maintained at Hold with Decreased Target to $21 on, Wednesday, October 4th, 2017
  • Liav Abraham of "Citigroup" Downgraded from Strong Buy to Hold on, Wednesday, August 16th, 2017
  • Tyler Van Buren of "Cowen & Co." Downgraded from Buy to Hold on, Friday, August 4th, 2017
  • Aaron Gal of "Bernstein" Downgraded from Buy to Hold on, Friday, August 4th, 2017
  • Derek Archila of "Oppenheimer" Downgraded from Buy to Hold on, Thursday, August 3rd, 2017
  • Irina Rivkind Koffler of "Mizuho" Upgraded from Sell to Hold on, Friday, June 16th, 2017
  • Louise Chen of "Cantor Fitzgerald" Initiated at Hold and Held Target at $31 on, Thursday, June 15th, 2017


These are the ratings of the 3 analyists that currently disagree with David


  • Tim Chiang of "BTIG" Upgraded from Hold to Strong Buy and Held Target at $24 on, Monday, September 11th, 2017
  • Vamil Divan of "JMP Securities" Maintained at Sell with Increased Target to $14 on, Wednesday, September 6th, 2017
  • Randall Stanicky of "RBC Capital" Downgraded from Buy to Sell on, Friday, August 4th, 2017
Contributing Sources